MannKind Corporation announced that a target action date was set for the pediatric use of inhaled insulin, involving the FDA.
2 reports, 2 independent
Updated May 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MannKind Corporation announced that a target action date was set for the pediatric use of inhaled insulin, involving the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- MannKind Corporation met with the FDA regarding its plan file for approval.Sub-event
Target action date set for pediatric use of inhaled insulin for MannKind Corporation.1 source
Keep exploring
The entities involved
- FDA
-
Ajay Ahuja
English writer and businessperson
Nothing else this week.
Coverage
Newest first; wire copies grouped- manilatimes.net
- Insider MonkeyMannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza We recently published 10 Best Biotech Stocks to Buy Under $10. MannKind Corporation stands fifth among them. MannKind Corporation